These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12806858)

  • 1. [Are hormone substitution and vitamins dangerous for elderly women with heart diseases?].
    Schenck-Gustafsson K
    Lakartidningen; 2003 May; 100(20):1784-6. PubMed ID: 12806858
    [No Abstract]   [Full Text] [Related]  

  • 2. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 3. Summaries for patients: The effect of estrogen plus progestin on coronary heart disease.
    Ann Intern Med; 2010 Feb; 152(4):I-40. PubMed ID: 20157120
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Langer RD
    Am J Epidemiol; 2009 Mar; 169(6):784-5; author reply 785-6. PubMed ID: 19208722
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial.
    Kelemen M; Vaidya D; Waters DD; Howard BV; Cobb F; Younes N; Tripputti M; Ouyang P
    Atherosclerosis; 2005 Mar; 179(1):193-200. PubMed ID: 15721027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitamin E for prevention of arteriosclerosis, coronary heart disease and cancer. Antioxidants--what is their value? Minerals, Vitamins & Co. Series, 6: Beta-carotene, vitamin C and E].
    Pannewig K
    Fortschr Med; 1998 Oct; 116(29):61-2. PubMed ID: 9846478
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormone replacement therapy and risk of heart disease.
    Elliott KK
    Am Fam Physician; 1999 Nov; 60(8):2234, 2237. PubMed ID: 10593314
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Wood C; Cline M
    J Natl Cancer Inst; 2008 Sep; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
    Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
    Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
    [No Abstract]   [Full Text] [Related]  

  • 10. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of estrogen-progestins in secondary prevention].
    Modena MG; Origliani G; Rossi R
    Ital Heart J Suppl; 2000 Mar; 1(3):435-6. PubMed ID: 10815281
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy].
    Stjernquist M;
    Lakartidningen; 2003 May; 100(20):1790-7. PubMed ID: 12806859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on cardiovascular health: hormone replacement therapy, estrogen replacement therapy, and selective estrogen receptor modulators.
    Walsh BW
    J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S6-8. PubMed ID: 12625632
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
    Ozcagli E; Sardas S; Biri A
    Maturitas; 2005 Jul; 51(3):280-5. PubMed ID: 15978971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy to prevent coronary events.
    Richard D; Newton WP
    J Fam Pract; 1998 Nov; 47(5):333-4. PubMed ID: 9834761
    [No Abstract]   [Full Text] [Related]  

  • 18. Coronary heart disease in women.
    Stevenson JC; Flather M; Collins P
    N Engl J Med; 2000 Dec; 343(25):1891; author reply 1892-3. PubMed ID: 11117985
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women.
    Carr BR; Khan N; Adams-Huet B; Kakarla N; Havelock JC; Gell J
    Fertil Steril; 2006 Mar; 85(3):667-73. PubMed ID: 16500336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination hormone replacement therapy and dementia.
    Wooltorton E
    CMAJ; 2003 Jul; 169(2):133. PubMed ID: 12874164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.